Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Aegerion Pharmaceuticals, Inc. (AEGR), Joint Corp (JYNT), Trillium Therapeutics Inc. (TRIL): Latest Fund Moves in the Hot Healthcare Sector

Page 1 of 2

At Insider Monkey, we track over 700 of the top hedge funds in the world, following and reporting on their latest moves disclosed through filings with the Securities and Exchange Commission on a daily basis. In this article we will cover three recent filings, involving three different funds and three different companies. Therefore, in the filings, Alex Denner’s Sarissa Capital, Glenn J. Krevlin’s (pictured) Glenhill Advisors, and Wayne Holman’s Ridgeback Capital Management. The companies in question are a trio of firms operating in the health sector, Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), Joint Corp (NASDAQ:JYNT), and Trillium Therapeutics Inc. (NASDAQ:TRIL).

Glenn Krevlin

However, we don’t just track the latest moves of funds. We are, in fact, more interested in their 13F filings, which we use to determine the top 15 small-cap stocks held by the funds we track. We gather and share this information based on 16 years of research, with backtests for the period between 1999 and 2012 and forward testing for the last 2.5 years. The results of our analysis show that these 15 most popular small-cap picks have a great potential to outperform the market, beating the S&P 500 Total Return Index by nearly one percentage point per month in backtests. Moreover, since the beginning of forward testsing August, 2012, the strategy worked splendidly, outperforming the market every year and returning 132% through March 11, which is by 79 percentage points higher than the returns of the S&P 500 ETF (SPY) (see more details).

We’ll start with Sarissa Capital and Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR). A recent filing detailed an agreement between the investor and the company, which involves the appointment of a new independent director to Aegerion’s Board of Directors, increasing its total membership to eight members. The agreement also allows Sarissa to appoint an additional class II director to the board at any time between January 2016 and two days following the company’s 2016 Annual Meeting of shareholders.

The deal and participation on the board are contingent upon Sarissa maintaining ownership of at least 1.20 million shares of Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR). Sarissa reported ownership of 1.64 million shares in a filing in early February, which was a new position for the activist fund and amounted to 5.76% of the company’s common stock. Matt Sirovich and Jeremy Mindich’s Scopia Capital is the largest shareholder among the funds we track, owning 5.35 million shares. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)’s stock has collapsed by nearly 75% from their peak in late 2013 and are down 26% over the past six months. The brunt of that loss occurred on October 31 after a weak earnings report and reduced full-year guidance crippled shares by 40%.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!